LobbyingBiomarin Pharmaceutical lobbying by quarter
Biomarin Pharmaceutical BMRN's latest lobbying report covers Q2 2026, at $390K. The four quarters Q4 2025–Q3 2026 total $1.4M. Its first report covers Q2 2017; the issues it reports most are Health Issues and Medicare/Medicaid.
Biomarin PharmaceuticalBMRN
- Latest quarter
- No record
- Q3 2026 · 0 reports
- Last 12 months
- $1.4M
- Last 4 quarters
- vs last quarter
- −100.0%
- Q3 2026 against the quarter before
- First report
- Q2 2017
- The first quarter a report named it
Lobbying by quarter
| Quarter | Amount | Reports |
|---|---|---|
| Q2 2017 | $30K | 1 |
| Q3 2017 | $0 | 0 |
| Q4 2017 | $0 | 0 |
| Q1 2018 | $0 | 0 |
| Q2 2018 | $0 | 0 |
| Q3 2018 | $0 | 0 |
| Q4 2018 | $0 | 0 |
| Q1 2019 | $0 | 0 |
| Q2 2019 | $0 | 0 |
| Q3 2019 | $0 | 0 |
| Q4 2019 | $0 | 0 |
| Q1 2020 | $0 | 0 |
| Q2 2020 | $0 | 0 |
| Q3 2020 | $0 | 0 |
| Q4 2020 | $0 | 0 |
| Q1 2021 | $0 | 0 |
| Q2 2021 | $0 | 0 |
| Q3 2021 | $0 | 0 |
| Q4 2021 | $0 | 0 |
| Q1 2022 | $0 | 0 |
| Q2 2022 | $0 | 0 |
| Q3 2022 | $0 | 0 |
| Q4 2022 | $450K | 2 |
| Q1 2023 | $420K | 2 |
| Q2 2023 | $280K | 2 |
| Q3 2023 | $270K | 2 |
| Q4 2023 | $520K | 2 |
| Q1 2024 | $460K | 2 |
| Q2 2024 | $230K | 2 |
| Q3 2024 | $290K | 2 |
| Q4 2024 | $540K | 3 |
| Q1 2025 | $440K | 2 |
| Q2 2025 | $320K | 3 |
| Q3 2025 | $350K | 3 |
| Q4 2025 | $470K | 3 |
| Q1 2026 | $580K | 2 |
| Q2 2026 | $390K | 2 |
| Q3 2026 | $0 | 0 |
By issue
- Health issues$2.8M · 31 reports
- Medicare and Medicaid$2.1M · 19 reports
- Tariffs$558.7K · 6 reports
- Taxation$318K · 6 reports
- Budget and appropriations$138K · 3 reports
- Medical research and clinical labs$85K · 1 reports
- Pharmacy$30K · 3 reports
- Immigration$6,000 · 1 reports
An issue's amount splits each report's amount equally over the issues the report lists.
Who was lobbied
- HOUSE OF REPRESENTATIVES33 reports
- SENATE32 reports
- Health & Human Services, Dept of (HHS)11 reports
- Food & Drug Administration (FDA)6 reports
- Commerce, Dept of (DOC)4 reports
- Executive Office of the President (EOP)3 reports
- White House Office3 reports
- Centers For Medicare and Medicaid Services (CMS)1 reports
- Government Accountability Office (GAO)1 reports
- Health Resources & Services Administration (HRSA)1 reports
Firms it paid
| Firm | ||
|---|---|---|
| In-houseBiomarin Pharmaceutical | $5.3M | 15 quarters |
| BGR Government Affairs | $670K | 14 quarters |
| LMH Strategic Solutions | $60K | 3 quarters |
| Chamber Hill Strategies | $30K | 1 quarters |
| Venn Strategies | $30K | 1 quarters |
| Holland & Knight | $0 | 1 quarters |
Former officials lobbying for it
| Former position | ||
|---|---|---|
| BRENT ALAN DEL MONTE | Leg. Dir. Rep. Bliley; Sen. Counsel House Energy & Commerce Committee | Q2 2026 |
| DANIEL FARMER | Intern, Staff Asst, Leg. Corr./Leg. Asst. for Rep. Debbie Wasserman Schultz; Leg. Asst., Sr. Leg. Asst., Leg. Dir. for Zack Space | Q2 2026 |
| DANIEL MAYNE | SENIOR REGULATORY HEALTH CONSULTANT- FOOD & DRUG ADMINISTRATION (6/2020-2/2022); REGULATORY POLICY ANALYST- FOOD & DRUG ADMINISTRATION (9/2023-6/2024) | Q2 2026 |
| JAMES WILLIAMS | Special Assist. to the Pres., WH Domestic Policy Council, 2019-2021; Economist, WH Council of Economic Advisors, 2017-2019 | Q2 2026 |
| JOEL D. BAILEY | COS Rep. Panetta; LD Rep. Ashford; LD Rep. Matheson; Sr. LA Rep. Matsui; LA, Sr. LA Rep. Baron Hill; Intern Rep. Rahall | Q2 2026 |
| JOHN STONE | Counsel, House E&C Cmte, Oversight Subcommittee; Senior Counsel, House E&C Cmte, Health Subcommittee; Intern, House E&C | Q2 2026 |
| REMY LEIGH BRIM MASON | Senior FDA Policy Advisor to Senate HELP Committee Ranking Member Patty Murray; Senior Health Policy Advisor Sen. Elizabeth Warren; Intern to Rep. Allyson Schwartz | Q2 2026 |
| ALANNA TEMME | Legislative Director, U.S. Representative Jon Porter | Q4 2025 |
| ROBB WALTON | Senior Health Policy Advisor and Counsel Sen Cassidy; Advisor Rep. Cassidy; Research Asst., Staff Asst., Intern on Senate HELP, Ranking Member, Sen. Enzi; Intern to Rep. Nunes | Q3 2025 |
| MELISSA BARTLETT | Counsel, U.S. House of Representatives, Committee on Energy and Commerce | Q4 2022 |
| ELIZABETH LEE | Senior Policy Advisor to the Administrator of the Health Resources and Services Administration, legislative aide to Senator Tammy Baldwin | Q2 2017 |
| MICHAEL SPIRA | Chief of Staff for former Congresswoman Carolyn McCarthy (D-NY) and Deputy Chief of Staff for Congressman Ed Perlmutter (D-CO) | Q2 2017 |
| TIM CAREY | Legislative Director for U.S. Representative Brad Sherman (D-CA), Deputy Legislative Director for Representative Anna G. Eshoo (D-CA | Q2 2017 |
Lobbying reports
| Filed by | ||
|---|---|---|
| 07/20for Q2 | In-house | $340K |
| 07/20for Q2 | In-house | $340K |
| 07/20for Q2 | In-house | $340K |
| 07/20for Q2 | BGR Government Affairs | $50K |
| 07/06for Q2 2017 | Venn Strategies | $30K |
| 04/20for Q1 | In-house | $530K |
| 04/20for Q1 | BGR Government Affairs | $50K |
| 04/17for Q4 2025 | LMH Strategic Solutions | $30K |
| 01/20for Q4 2025 | In-house | $390K |
| 01/20for Q4 2025 | BGR Government Affairs | $50K |
| 01/12for Q4 2025 | LMH Strategic Solutions | $30K |
| 25/10/20for Q3 2025 | In-house | $270K |
| 25/10/20for Q3 2025 | BGR Government Affairs | $50K |
| 25/10/20for Q3 2025 | LMH Strategic Solutions | $30K |
| 25/10/06for Q2 2025 | LMH Strategic Solutions | Under $5,000 |
| 25/07/21for Q2 2025 | LMH Strategic Solutions | $10K |
| 25/07/21for Q2 2025 | In-house | $270K |
| 25/07/21for Q2 2025 | BGR Government Affairs | $50K |
| 25/07/15for Q2 2025 | LMH Strategic Solutions | Under $5,000 |
| 25/04/21for Q1 2025 | In-house | $390K |